Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 425-428 , September 2010

Web-based application to project the burden of Alzheimer's disease

References 

  1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337–1342
  2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3:186–191
  3. Murray CJ, Lopez AD. Quantifying disability: data, methods and results. Bull World Health Organ. 1994;72:481–494
  4. Gustavsson A, Van Der Putt R, Jönsson L, McShane R. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2009;24:1072–1078
  5. Weimer DL, Sager MA. Early identification and treatment of Alzheimer's disease: social and fiscal outcomes. Alzheimers Dement. 2009;5:215–226
  6. Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. World population prospects. Available at: http//esa.un.org/unpp. Accessed March 8, 2006.
  7. United States Census Bureau. National population projections. Available at: http://www.census.gov/population/www/projections/natdet-D1A.html. Accessed March 26, 2007.
  8. University of California, Berkeley (USA) and Max Planck Institute for Demographic Research (Germany). Human mortality database. Available at: www.mortality.org or www.humanmortality.de. Accessed December 6, 2005.
  9. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide variation in the doubling time of Alzheimer's disease incidence rates. Alzheimers Dement. 2008;4:316–323
  10. Stern Y, Tang X, Albert MS, Brandt J, Jacobs DM, Bell K, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA. 1997;277:806–812
  11. Alzheimer's Association. 2009 Alzheimer's facts and figures. Alzheimers Dement. 2009;5:234–270
  12. Johnson E, Brookmeyer R, Ziegler-Graham K. Modeling the effect of Alzheimer's disease on mortality. Int J Biostat 2007;3:Article 13. Available at http://www.bepress.com/ijb/vol3/iss1/13.
  13. Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramer PGN, van de Water HPA, et al. Disability weights for diseases in the Netherlands. Rotterdam, Netherlands: Department of Public Health; 1997;
  14. Murray CJL. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull World Health Organ. 1994;72:429–445
  15. United States Census Bureau, Population Division. Interim state population projections, 2005. Available at: http://www.census.gov/population/projections/DownldFile4.csv. Accessed October 21, 2009.
  16. Fox PJ, Kohatsu N, Max W, Arnsberger P. Estimating the costs of caring for people with Alzheimer disease: 2000–2040. J Public Health Policy. 2001;22:88–97

 Conflict of interest: H Michael Arrighi was an employee of and owns stock in Elan and is currently an employee of JANSSEN Alzheimer Immunotherapy Research & Development, LLC.

PII: S1552-5260(10)00041-5

doi: 10.1016/j.jalz.2010.01.014

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 6, Issue 5 , Pages 425-428 , September 2010